---
figid: PMC4002321__aps2010150f2
figtitle: PI3K/Akt pathway involved in tumorigenesis
organisms:
- NA
pmcid: PMC4002321
filename: aps2010150f2.jpg
figlink: /pmc/articles/PMC4002321/figure/fig2/
number: F2
caption: 'PI3K/Akt pathway involved in tumorigenesis. After activation by RTKs or
  Ras, PI3K catalyzes the phosphorylation of PIP2 to generate PIP3, which activates
  Akt and PDK. Akt can also be activated by PDK and mTOR complex 2 (mTORC2, rictor-mTOR),
  other than direct activation by PIP3. By increasing the level of cyclin D1, and
  reducing the level of Cdk (cyclin dependent kinase) inhibitor p27, Akt promotes
  the cell cycle progression. Akt also acts to maintain cell survival by phosphorylation
  of BAD and release of the anti-apoptotic protein Bcl-2. Furthermore, Akt controls
  cell growth by phosphorylation of the downstream mTOR complex 1 (mTORC1, raptor-mTOR),
  which promotes translation of mRNAs to synthesize protein via p70S6K-S6 and 4E-BP1-eIF4E
  pathways. In addition, HIF-1α is up-regulated downstream of mTORC1, and then promotes
  angiogenesis via enhancing transcription of VEGF. However, the mTORC1/S6K cascade
  negatively regulates IRS, which leads to a feedback loop. PDK: 3-Phosphoinositide-dependent
  protein kinase; GSK3: glycogen synthesis kinase 3; FOXO: forkhead; p70S6K: p70S6
  kinase; 4E-BP1: 4E-binding protein 1; IRS: insulin receptor substrate; HIF-1α: hypoxia-inducible
  factor 1α VEGF: vascular endothelial growth factor.'
papertitle: ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using
  the JFCR39 drug discovery system.
reftext: De-xin Kong, et al. Acta Pharmacol Sin. 2010 Sep;31(9):1189-1197.
year: '2010'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9743129
figid_alias: PMC4002321__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC4002321__F2
ndex: 14312cd4-dec2-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4002321__aps2010150f2.html
  '@type': Dataset
  description: 'PI3K/Akt pathway involved in tumorigenesis. After activation by RTKs
    or Ras, PI3K catalyzes the phosphorylation of PIP2 to generate PIP3, which activates
    Akt and PDK. Akt can also be activated by PDK and mTOR complex 2 (mTORC2, rictor-mTOR),
    other than direct activation by PIP3. By increasing the level of cyclin D1, and
    reducing the level of Cdk (cyclin dependent kinase) inhibitor p27, Akt promotes
    the cell cycle progression. Akt also acts to maintain cell survival by phosphorylation
    of BAD and release of the anti-apoptotic protein Bcl-2. Furthermore, Akt controls
    cell growth by phosphorylation of the downstream mTOR complex 1 (mTORC1, raptor-mTOR),
    which promotes translation of mRNAs to synthesize protein via p70S6K-S6 and 4E-BP1-eIF4E
    pathways. In addition, HIF-1α is up-regulated downstream of mTORC1, and then promotes
    angiogenesis via enhancing transcription of VEGF. However, the mTORC1/S6K cascade
    negatively regulates IRS, which leads to a feedback loop. PDK: 3-Phosphoinositide-dependent
    protein kinase; GSK3: glycogen synthesis kinase 3; FOXO: forkhead; p70S6K: p70S6
    kinase; 4E-BP1: 4E-binding protein 1; IRS: insulin receptor substrate; HIF-1α:
    hypoxia-inducible factor 1α VEGF: vascular endothelial growth factor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IRSp53
  - IleRS
  - chico
  - Pten
  - Pdk
  - Pdk1
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - ras
  - Ras64B
  - Ras85D
  - Crtc
  - Akt
  - Raf
  - sgg
  - cass
  - S6k
  - foxo
  - Dsor1
  - Mtk
  - Thor
  - sima
  - tgo
  - Debcl
  - DCTN6-p27
  - dap
  - CG9588
  - MKP-4
  - p38b
  - rl
  - eIF4E1
  - eIF4E7
  - eIF4E4
  - eIF4E5
  - eIF4E3
  - eIF4E6
  - eIF4EHP
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - CycE
  - cyc
  - Tie
  - InR
  - Myb
  - Taf5
  - l(1)G0020
  - Taf4
  - Rpn2
  - Sap-r
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - IARS1
  - IRS1
  - IRS2
  - IRS4
  - PTEN
  - PDK1
  - PDK2
  - PDK3
  - PDK4
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - CRTC2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - RPTOR
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - GSK3A
  - GSK3B
  - BAD
  - RPS6KB1
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EIF4EBP1
  - HIF1A
  - ARNT
  - BCL2
  - CCND1
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - EIF4E
  - EIF4E2
  - EIF4E3
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - CUX1
  - SART3
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
